Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.

@article{NguyenTan2014RandomizedPI,
  title={Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.},
  author={Phuc Felix Nguyen-Tan and Qiang Zhang and Kian K. Ang and David E. Schuller and David I. Rosenthal and Denis Souli{\'e}res and Harold E. Kim and Craig L. Silverman and Anne Raben and Thomas J Galloway and A Bonneau Fortin and Elizabeth Gore and William H Westra and Christine H. Chung and Richard C K Jordan and Maura L. Gillison and Marcy A. List and Quynh-Thu Le},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 34},
  pages={
          3858-66
        }
}
PURPOSE We tested the efficacy and toxicity of cisplatin plus accelerated fractionation with a concomitant boost (AFX-C) versus standard fractionation (SFX) in locally advanced head and neck carcinoma (LA-HNC). PATIENTS AND METHODS Patients had stage III to IV carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Radiation therapy schedules were 70 Gy in 35 fractions over 7 weeks (SFX) or 72 Gy in 42 fractions over 6 weeks (AFX-C). Cisplatin doses were 100 mg/m(2) once every 3… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 82 CITATIONS, ESTIMATED 41% COVERAGE

Emerging insights into recurrent and metastatic human papillomavirus‐related oropharyngeal squamous cell carcinoma

  • Laryngoscope investigative otolaryngology
  • 2017
VIEW 12 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Human Papillomavirus-Negative Pharyngeal Cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 14 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 16 Citations per year from 2017 through 2019